A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis

Bárour Sigurgeirsson*, Koen Van Rossem, Steven Malahias, Kerry Raterink

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)

Abstract

Background: Onychomycosis is effectively treated with terbinafine and itraconazole. However, frequent repeated dosing is required, and hepatic and cardiac adverse events may occur. Objectives: Evaluate efficacy and safety of albaconazole, a novel triazole, for once-weekly treatment of distal subungual onychomycosis of the great toenail. Methods: This double-blind, phase II study randomized 584 patients to receive albaconazole 100 to 400 mg or placebo weekly for 24 or 36 weeks. Effective treatment was measured as mycologic cure and clear or almost clear nail at week 52. Results: All treatment groups achieved greater effective treatment rates (21%-54%) compared to placebo (1%; P <.001 for all groups) at week 52. Effective treatment was attained at week 24 in ≥5% of patients in most groups. Most adverse events were mild or moderate, and treatment-related adverse events were all ≤3%. No treatment-related hepatic or cardiac serious adverse events were observed. Limitations: The follow-up period was likely too short to detect maximal efficacy; cure rates were increasing at study end. The efficacy and tolerability of albaconazole were not compared with other available treatments, and the global change in target toenail scale was subjective. Conclusions: Albaconazole was well tolerated at all doses and resulted in high cure rates for onychomycosis.

Original languageEnglish
Pages (from-to)416-425.e1
JournalJournal of the American Academy of Dermatology
Volume69
Issue number3
DOIs
Publication statusPublished - Sept 2013

Other keywords

  • albaconazole
  • dermatophyte
  • nail fungus
  • onychomycosis
  • phase II study
  • triazole

Fingerprint

Dive into the research topics of 'A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis'. Together they form a unique fingerprint.

Cite this